论文部分内容阅读
目的:了解南京地区二肽基肽酶-4(DPP-4)抑制药的应用近况和发展趋势,为临床合理用药提供参考。方法:根据长江流域医药情报研究所提供的南京地区样本医院2013~2015年口服降糖药的统计数据,采用限定日剂量分析法,对该地区34家样本医院近三年包括DPP-4抑制药在内的所有口服降糖药的销售金额、用药频度(DDDs)和限定日费用(DDC)等进行回顾性统计。结果:南京地区口服降糖药的总销售金额和总DDDs都呈上升趋势,各类药物的销售金额和DDDs排名基本稳定,2015年DPP-4抑制药的DDDs和销售金额在所有口服降糖药中所占份额相比2013年已翻倍,是增长速度最快的口服降糖药,但其DDC值较高,价格也相对偏高。结论:2013~2015年口服降糖药需求量逐年增加,以DPP-4抑制药为代表的新型口服降糖药为血糖控制提供了一条新的研究路径,反映了当前2型糖病治疗的新方向。
Objective: To understand the status quo and development trend of DPP-4 inhibitor in Nanjing area and provide a reference for clinical rational drug use. Methods: According to the statistical data of oral hypoglycemic agents in Nanjing Regional Sample Hospital from 2013 to 2015 provided by Institute of Medical Intelligence of the Yangtze River Basin, the daily dose analysis method was used to determine the effect of DPP-4 inhibitor in 34 sample hospitals in the region , Including the sales amount of all the oral hypoglycemic agents, DDDs and DDC. Results: The total sales amount and total DDDs of oral hypoglycemic agents in Nanjing showed an upward trend. The sales amount and DDDs ranking of all kinds of drugs were basically stable. The DDDs and sales amount of DPP-4 inhibitors in 2015 were lower than those in all oral hypoglycemic agents In the share has doubled compared to 2013, is the fastest growing oral hypoglycemic drugs, but its higher DDC value, the price is relatively high. Conclusion: The demand for oral hypoglycemic agents increased year by year from 2013 to 2015. A new oral hypoglycemic agent represented by DPP-4 inhibitor provided a new research route for glycemic control, reflecting the new treatment of type 2 diabetes direction.